|
|
Post by Clement on Jan 4, 2019 16:54:21 GMT -5
On Nov 3, Lakers posted: "KEY FINDINGS OF THE CINV MARKET STUDY The Aloxi segment generated highest revenue in the global market in 2015, accounting for over half of the total market. The Netupitant- Palonosetron FDC segment is the fastest growing segment at a CAGR of 10.8%. The North American market has witnessed a significant growth in the recent years. Presently, it is the largest regional market for CINV drugs and an its market share is anticipated by 2022. Asia-Pacific is the fastest growing market due to increase in number of cancer population, high incidences of gastroenteritis and other diseases that lead to nausea and vomiting. This region boosts up the demand for antiemetic drug due to growth in demand for CINV drugs and is expected to fuel the market growth in this region. Partnership and collaboration is the key strategy adopted by companies to strengthen their position in the market. The key major players in the global chemotherapy-induced nausea and vomiting drugs are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc. Teva Announces the Launch of a Generic Version of ALOXI® in the United States JERUSALEM--(BUSINESS WIRE)--Mar. 23, 2018-- Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced the launch of a generic version of ALOXI®1 ( palonosetron HCI) injection, 0.25 mg/5 mL, in the United States. Palonosetron hydrochloride injection—in a class of medications called 5-HT3 receptor antagonists—is used in adults to prevent nausea and vomiting that may occur as a result of receiving cancer chemotherapy with a moderate or high risk of causing nausea and vomiting. It is also given to prevent nausea and vomiting up to 24 hours after surgery. “The shared-exclusive launch of palonosetron HCI injection marks the eleventh injectable launch over the past year for our generics business,” said Brendan O’Grady, Executive Vice President and head of North America Commercial at Teva. “More importantly, we can now provide an affordable treatment option for cancer patients faced with challenging post-chemotherapy side effects.” www.tevapharm.com/news/teva_announces_the_launch_of_a_generic_version_of_aloxi_in_the_united_states_03_18.aspxRead more: mnkd.proboards.com/thread/10587/mannkind-conference-call-nov-1st#ixzz5bg74TKnr |
|
|
|
Post by Clement on Jan 4, 2019 16:57:56 GMT -5
At some point in time, palonosetron was in bucket 2 as I recall.
|
|
|
|
Post by mango on Jan 4, 2019 20:29:40 GMT -5
|
|
|
|
Post by kc on Jan 4, 2019 21:06:42 GMT -5
Mike said the Undisclosed molecule was consumer driven and is on hush due to competitive reasons. Sorry for being so crude but that might be better than sex if the consumer driven molecule gives some of us a stiffy.........  are there any board members who will volunteer for the stiffy trials? |
|
|
|
Post by kc on Jan 4, 2019 21:13:15 GMT -5
|
|
|
|
Post by mnholdem on Jan 5, 2019 0:00:03 GMT -5
This sounds interesting ya'll "Take the migraine for example. I look at Novartis, Lilly and Teva all have built large chronic prevention sales forces for migraines. No one is now treating the acute episode, that’s still occurring after time. And I believe that there will be an opportunity in the migraines space where a better triptan deliver faster onset because that’s what people were going to expect that day. They’ve diminished the number of frequencies of chronic migraines, but now they can address the acute ones which are still pretty severe, a lot less frequent but if we get a better onset in that particular setting that’s an area we’re focused on sort like the triptan." "On the chemotherapy-induced nausea and vomiting one, we look at this as again we saw some pulmonary data out there in the marketplace that would highlight an inhaled version of these products. We get a fast onset. We think it needs a unique profile and there’s a lot of companies building Oncology sales forces who will just need another product in the bag. A single product sales force as we look out, we’ve made it through the worst but not an easy journey for the company and I think that’s something that we’re hearing more and more from Wall Street is they want people to have more shots on goal, and we have a pipeline fortunately moving forward now. That’s just a couple of examples of how we look at the pipeline." Patent protection for Sumatriptan expired quite some time ago and the API is manufactured as a generic by a number of companies, such as Sun Pharma in India. That means lower cost and higher margin. I've long hoped that Glaxo-Smith-Kline would approach MannKind to develop Imitrex-TS (aka Sumatriptan-TS) to complement Imitrex by introducing a fast-acting migraine. Pre-clinical studies conducted by MannKind indicated pain relief in as little as five minutes. Most oral triptans (there are several types) take about an hour to relieve pain and that's only if taken at the first sign of a migraine treatment. They can be ineffective if taken later. Technosphere's version would be incredibly fast. |
|
|
|
Post by centralcoastinvestor on Jan 5, 2019 0:27:55 GMT -5
This sounds interesting ya'll "Take the migraine for example. I look at Novartis, Lilly and Teva all have built large chronic prevention sales forces for migraines. No one is now treating the acute episode, that’s still occurring after time. And I believe that there will be an opportunity in the migraines space where a better triptan deliver faster onset because that’s what people were going to expect that day. They’ve diminished the number of frequencies of chronic migraines, but now they can address the acute ones which are still pretty severe, a lot less frequent but if we get a better onset in that particular setting that’s an area we’re focused on sort like the triptan." "On the chemotherapy-induced nausea and vomiting one, we look at this as again we saw some pulmonary data out there in the marketplace that would highlight an inhaled version of these products. We get a fast onset. We think it needs a unique profile and there’s a lot of companies building Oncology sales forces who will just need another product in the bag. A single product sales force as we look out, we’ve made it through the worst but not an easy journey for the company and I think that’s something that we’re hearing more and more from Wall Street is they want people to have more shots on goal, and we have a pipeline fortunately moving forward now. That’s just a couple of examples of how we look at the pipeline." Patent protection for Sumatriptan expired quite some time ago and the API is manufactured as a generic by a number of companies, such as Sun Pharma in India. That means lower cost and higher margin. I've long hoped that Glaxo-Smith-Kline would approach MannKind to develop Imitrex-TS (aka Sumatriptan-TS) to complement Imitrex by introducing a fast-acting migraine. Pre-clinical studies conducted by MannKind indicated pain relief in as little as five minutes. Most oral triptans (there are several types) take about an hour to relieve pain and that's only if taken at the first sign of a migraine treatment. They can be ineffective if taken later. Technosphere's version would be incredibly fast. My wife gets migraines and she says that it would be a miracle to have the medicine work in 5 minutes. It’s agony to wait the hour before the Imitrex works. And if you mistime the onset, the migraine continues to get worse. Then its off to the emergency room. |
|
|
|
Post by mango on Jan 5, 2019 3:32:30 GMT -5
Would vaccines be considered consumer driven? Bucket 3 |
|
|
|
Post by lakon on Jan 6, 2019 11:29:36 GMT -5
Is consumer driven synonymous with recreational?
|
|
|
|
Post by peppy on Jan 6, 2019 11:33:24 GMT -5
|
|
|
|
Post by peppy on Jan 6, 2019 11:39:03 GMT -5
|
|
|
|
Post by mnholdem on Jan 6, 2019 15:11:07 GMT -5
Of the three graphics posted by peppy (above) only the Pipeline graphic is displayed within MannKind's corporate website pages. I'm disappointed that there's such a large time lag between the dates that management discloses new information to the dates when that info gets published, within the website (R&D page for example) and in regular press releases. A picture is worth a thousand words and, although these graphics (above) illustrate the many applications for Technosphere and MannKind's R&D vision for its future, only those people who watched a webcast or who are interested enough to seek out the MannKind website and then navigate through the links to webcast archives ever see this information. How does the rest of the industry hear about important new information? Didn't MannKind hire an officer for marketing the company and its drugs & technology? This is such an easy task, what I call low-hanging fruit, so it's disturbing that important new information, like R&D planning, isn't disseminated by MannKind's marketing team to mass media or even to its own corporate website (links to companies often appear in articles published by the press). I've hired managers and specialists for 30 years in the aerospace, defense and medical device industries. I learned long ago that if you don't communicate expectations to new hires, with specific objectives and timelines, they often live up to your expectations or lack thereof. --- CEO stated in a conference call last week that MannKind will be launching a new marketing push in about a week. I hope their plan isn't to simply double down on their past efforts because two times zero still equals zero.  |
|
|
|
Post by mango on Jan 6, 2019 15:12:12 GMT -5
|
|
|
|
Post by mango on Jan 6, 2019 16:12:53 GMT -5
Of the three graphics posted by peppy (above) only the Pipeline graphic is displayed within MannKind's corporate website pages. I'm disappointed that there's such a large time lag between the dates that management discloses new information to the dates when that info gets published, within the website (R&D page for example) and in regular press releases. A picture is worth a thousand words and, although these graphics (above) illustrate the many applications for Technosphere and MannKind's R&D vision for its future, only those people who watched a webcast or who are interested enough to seek out the MannKind website and then navigate through the links to webcast archives ever see this information. How does the rest of the industry hear about important new information? Didn't MannKind hire an officer for marketing the company and its drugs & technology? This is such an easy task, what I call low-hanging fruit, so it's disturbing that important new information, like R&D planning, isn't disseminated by MannKind's marketing team to mass media or even to its own corporate website (links to companies often appear in articles published by the press). I've hired managers and specialists for 30 years in the aerospace, defense and medical device industries. I learned long ago that if you don't communicate expectations to new hires, with specific objectives and timelines, they often live up to your expectations or lack thereof. --- CEO stated in a conference call last week that MannKind will be launching a new marketing push in about a week. I hope their plan isn't to simply double down on their past efforts because two times zero still equals zero. Why wasn't the information just added on the website in advance and then updated after the CC? I feel like they're saving it for JPM heathcare conference & won't update anything until then, but actually won't be surprised if it's lagged more. Why isn't United mentioned in the pipeline with TreT? UT pretty much immediately put Technosphere on their pipeline page, and we have no visible indication they are even our partner on ours. The official Afrezza websites are pretty awesome, can we not just get whoever manages those to also do the corporate site? |
|
|
|
Post by golfeveryday on Jan 6, 2019 16:50:31 GMT -5
Of the three graphics posted by peppy (above) only the Pipeline graphic is displayed within MannKind's corporate website pages. I'm disappointed that there's such a large time lag between the dates that management discloses new information to the dates when that info gets published, within the website (R&D page for example) and in regular press releases. A picture is worth a thousand words and, although these graphics (above) illustrate the many applications for Technosphere and MannKind's R&D vision for its future, only those people who watched a webcast or who are interested enough to seek out the MannKind website and then navigate through the links to webcast archives ever see this information. How does the rest of the industry hear about important new information? Didn't MannKind hire an officer for marketing the company and its drugs & technology? This is such an easy task, what I call low-hanging fruit, so it's disturbing that important new information, like R&D planning, isn't disseminated by MannKind's marketing team to mass media or even to its own corporate website (links to companies often appear in articles published by the press). I've hired managers and specialists for 30 years in the aerospace, defense and medical device industries. I learned long ago that if you don't communicate expectations to new hires, with specific objectives and timelines, they often live up to your expectations or lack thereof. --- CEO stated in a conference call last week that MannKind will be launching a new marketing push in about a week. I hope their plan isn't to simply double down on their past efforts because two times zero still equals zero. Why wasn't the information just added on the website in advance and then updated after the CC? I feel like they're saving it for JPM heathcare conference & won't update anything until then, but actually won't be surprised if it's lagged more. Why isn't United mentioned in the pipeline with TreT? UT pretty much immediately put Technosphere on their pipeline page, and we have no visible indication they are even our partner on ours. The official Afrezza websites are pretty awesome, can we not just get whoever manages those to also do the corporate site? if I was a betting man, and I guess I am seeing I own mnkd shares, I would bet they announce some of the recent communication from last week during the JP Morgan conference. Voucher program, direct pay, new marketing campaign, expanded technosphere portfolio. Perfect time to launch a new corporate site as well. More promotion puts more eyes on the company and a new website would be appropriate followed by significant tv commercial expansion Jan 14th. |
|
